Categories: BioTechHealthTechLearnManagementPersonalScienceServiceTechnologyToolsWellness
Genomind is a biotechnology and digital service company bringing innovative solutions to treatment and medication management by combining advanced genomic science and precision technology.

Genomind® Professional PGx Express™ is an industry-leading prescription pharmacogenetic test that equips healthcare professionals with tools they need to more quickly identify a personalized treatment plan for their patients. We offer comprehensive genetic guidance, superior speed and accuracy, state-of-the-art digital tools, and On-Demand or schedule PhD and PharmD expert consultations so providers can give the highest quality of care. This test is available via clinician order only.

Genomind® Mental Health Map™ is the first-ever genetic test available direct-to-consumer designed specifically for mental wellness. It provides powerful new insights and actions through 7 in-depth reports analyzing mental health predispositions. Included is a free consult to help individuals better take advantage of their results. This test does not inform on medications nor require clinician order.

Genomind encourages and allows users to interact with its brand’s social channels, and will engage with users to remain as transparent as possible. That being said, Genomind will not allow vulgarity to remain on its channels. All comments or posts including harassment, hate speech or excessive amounts of harsh language will be hidden.
Likes
5.86K
Followers
4.15K
Website visits
75.4K /mo.
Mentions
7
Location: United States, Pennsylvania, King of Prussia
Employees: 51-200
Phone: +1 877-895-8658
Total raised: $11M
Founded date: 2009

Investors 1

Funding Rounds 2

DateSeriesAmountInvestors
24.09.2015-$6M-
09.04.2014Series A$5M-

Mentions in press and media 7

DateTitleDescription
19.07.2022Cosán and Genomind Partner to Help Prevent Adverse Prescription Drug Events for Older AdultsCosán and Genomind Partner to Help Prevent Adverse Prescription Drug Events for Older Adults Genomind’s analytic capabilities will provide Cosán with risk stratification insights, enabling Cosán clinicians to target individuals that are mos...
22.12.2020How pharmacogenetic (PGx) testing is revolutionizing mental health treatment(BPT) - If you or a family member have sought care from a mental health professional, or are considering seeking help for depression, anxiety, ADHD or other conditions, you want the best treatment available. Multiple treatment options now e...
22.12.2020How pharmacogenetic (PGx) testing is revolutionizing mental health treatment(BPT) - If you or a family member have sought care from a mental health professional, or are considering seeking help for depression, anxiety, ADHD or other conditions, you want the best treatment available. Multiple treatment options now e...
11.05.2018Dell Boomi, Perpay, Relay win 2018 PACT Enterprise AwardsFor the 25th Anniversary of the Enterprise Awards, the Philadelphia Alliance for Capital and Technology shook up both format and venue for the annual awards show, held Wednesday at the Kimmel Center for the Performing Arts. Shorter speeches...
24.09.2015Genomind Closes $6M Financing RoundGenomind, a King of Prussia, PA-based genetic testing company bringing innovation to mental health care, closed a $6m round of financing. The round was led by Claritas Capital, which had previously led a $5m investment round in Genomind in ...
11.04.2014Genomind Secures $5M in Series A CHALFONT, PA, Personalized medicine company, today announced the closing of a $5 million financing. >> Click here for more funding data on Genomind >> To export Genomind funding data to PDF and Excel, click here Genomind,...
09.04.2014Genomind Closes $5M FinancingGenomind, a Chalfont, PA-based personalized medicine company, closed a $5m financing. The round was led by Claritas Capital. The company intends to use the funds to grow operations and products. Led by Dr. Ronald I. Dozoretz, Co-Founder and...

Reviews 0

Sign up to leave a review

Sign up Log In